Wall Street analysts’ outlook for Citius Pharmaceuticals Inc. (CTXR)

Citius Pharmaceuticals Inc. (NASDAQ: CTXR) stock fell -15.00% on Tuesday to $1.19 against a previous-day closing price of $1.40. With 2.07 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.73 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $1.3900 whereas the lowest price it dropped to was $1.1900. The 52-week range on CTXR shows that it touched its highest point at $2.01 and its lowest point at $0.77 during that stretch. It currently has a 1-year price target of $7.00. Beta for the stock currently stands at 1.27.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…

Sponsored

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of CTXR was up-trending over the past week, with a rise of 5.31%, but this was up by 15.53% over a month. Three-month performance surged to 13.33% while six-month performance rose 32.53%. The stock lost -19.05% in the past year, while it has gained 50.63% so far this year. A look at the trailing 12-month EPS for CTXR yields -0.23 with Next year EPS estimates of 0.96. For the next quarter, that number is -0.04. This implies an EPS growth rate of -2.10% for this year and 123.26% for next year.

Float and Shares Shorts:

At present, 146.15 million CTXR shares are outstanding with a float of 133.82 million shares on hand for trading. On Dec 29, 2022, short shares totaled 10.96 million, which was 7.50% higher than short shares on Nov 29, 2022. In addition to Mr. Leonard L. Mazur as the firm’s Co-Founder, CEO, Chairman & Sec., Mr. Myron Z. Holubiak serves as its Co-Founder & Exec. Vice Chairman.

Institutional Ownership:

Through their ownership of 11.12% of CTXR’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 8.42% of CTXR, in contrast to 5.46% held by mutual funds. Shares owned by individuals account for 3.92%. As the largest shareholder in CTXR with 3.95% of the stake, The Vanguard Group, Inc. holds 5,770,263 shares worth 5,770,263. A second-largest stockholder of CTXR, BlackRock Fund Advisors, holds 2,310,819 shares, controlling over 1.58% of the firm’s shares. Geode Capital Management LLC is the third largest shareholder in CTXR, holding 1,323,296 shares or 0.91% stake. With a 2.71% stake in CTXR, the Vanguard Total Stock Market Index is the largest stakeholder. A total of 3,958,982 shares are owned by the mutual fund manager. The Vanguard Extended Market Index Fu, which owns about 1.24% of CTXR stock, is the second-largest Mutual Fund holder. It holds 1,818,366 shares valued at 1.44 million. Fidelity Extended Market Index Fu holds 0.49% of the stake in CTXR, owning 716,160 shares worth 0.57 million.


An Overview of Recent Financials:

Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on Sep 29, 2022, CTXR reported revenue of $0.00 and operating income of -$8.92M. The EBITDA in the recently reported quarter was -$8.82M and diluted EPS was -$0.06.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for CTXR since 2 analysts follow the stock currently. There are 2 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With CTXR analysts setting a high price target of $10.00 and a low target of $4.00, the average target price over the next 12 months is $7.00. Based on these targets, CTXR could surge 740.34% to reach the target high and rise by 236.13% to reach the target low. Reaching the average price target will result in a growth of 488.24% from current levels.


EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. CTXR will report FY 2023 earnings on 12/13/2023. Analysts have provided yearly estimates in a range of $0.43 being high and -$0.24 being low. For CTXR, this leads to a yearly average estimate of $0.10. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Citius Pharmaceuticals Inc. surprised analysts by -$0.01 when it reported -$0.06 EPS against a consensus estimate of -$0.05. The surprise factor in the prior quarter was -$0.01. Based on analyst estimates, the high estimate for the next quarter is -$0.04 and the low estimate is -$0.06. The average estimate for the next quarter is thus -$0.05.

Summary of Insider Activity:

Insiders traded CTXR stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has remained unchanged to 0 while that of sell transactions has remained unmoved to 0 over the past year. The total number of shares bought during that period was 0 while 0 shares were sold.

Leave a Comment

Your email address will not be published. Required fields are marked *